At Alfa Cytology, our comprehensive service provides an invaluable resource for identifying synergistic combinations of targeted small molecule inhibitors, enabling personalized and effective cancer treatment strategies.
Introduction to Drug Screening
With advancements in technology and a deeper understanding of cancer biology, the demand for efficient drug screening services has grown exponentially. Drug screening, particularly high-throughput screening (HTS), has revolutionized the process of identifying chemical leads for drug development. By rapidly evaluating thousands of unique small molecules, drug screening enables the identification of compounds that exhibit potential anti-cancer activity.
Fig.1 Using a diverse set of rhabdoid tumor cell lines and both small-molecule and CRISPR-Cas9 gene-knockout screening. (Oberlick, E. M., et al., 2019)
Significance of Drug Screening in Oncology
The field of oncology faces unique challenges due to the complexity and heterogeneity of cancer. Traditional drug development approaches often struggle to keep pace with the rapid advancements in our understanding of cancer biology. Drug screening offers a solution by providing a comprehensive and systematic approach to identify promising compounds with anti-cancer properties. By exploring diverse chemical spaces, drug screening allows for the discovery of novel targets and mechanisms of action.
Our Services
Alfa Cytology is your trusted partner in the field of anti-cancer drug screening. Our expertise in preclinical research and commitment to excellence enable us to provide cutting-edge solutions tailored to your specific needs. Our services include, but are not limited to:
High-Throughput Screening (HTS)
Our HTS platforms incorporate biologically and physiologically relevant assays, ensuring that the selected molecules have the highest probability of success in subsequent stages of drug development.
Mechanism-Informed Phenotypic Drug Discovery
Alfa Cytology excels in mechanism-informed phenotypic drug discovery, where we combine our understanding of disease biology with high-quality screening data to identify small molecules with desired phenotypic effects.
Combination Screening
Alfa Cytology offers combination screening services to identify synergistic drug combinations with enhanced efficacy and reduced toxicity. By testing individual drugs and their pairwise combinations, we provide our clients with a vast dataset of drug combination responses.
Expert Analysis and Interpretation
We support our clients unraveling the complex interactions between small molecule inhibitors and cancer cell viability. By employing statistical analyses and synergy metrics such as Bliss independence, we identify combinations that synergistically reduce cancer cell viability.
Our Advantages
Largest Toolbox
Strong Expertise
One-stop Solution
Short Turnaround
Alfa Cytology is revolutionizing the field of small molecule anti-cancer drug screening through our comprehensive services and commitment to open science. By employing high-throughput screening techniques, providing openly accessible datasets, and offering expert analysis, we empower researchers to explore synergistic combinations of targeted small molecule inhibitors. If you are interested in our service, please contact us for more details.
Reference
-
Oberlick, E. M., et al.; (2019). Small-molecule and CRISPR screening converge to reveal receptor tyrosine kinase dependencies in pediatric rhabdoid tumors. Cell reports, 28(9), 2331-2344.
For research use only.
Related Services
